> My father is 70 and he is fighting is second colorectal cancer.  The
> first one was surgically removed 2-3 years ago, but a second tumor
> rapidly appeared.  He has gone through radiotherapy and chemiotherapy
> for the past 18 months or so, and he has a tumor which doctors cannot
> remove because it is "too invasive" and the operation would likely
> kill him.  Chemiotherapy has apparently reduced slightly the size of
> the tumor, but it still cannot be removed surgically.  Doctors
> continue to provide him with "short" chemiotherapy sessions (6-8
> weeks) with scans and {*filter*} samples in-between, but they never made
> any statement about a possible outlook.  Sure, it is not a an exact
> science.  Nevertheless I don't expect him to go through chemiotherapy
> for another 10 years.

> I tried to find statistics about the life expectancy of someone with a
> "non-removable" colon tumor (whatever what stage this is, we've never
> been told) but could not find anything on the subject.  If anyone has
> links to point to or similar stories, please let me know.  thanks.

> Paul

> My father is 70 and he is fighting is second colorectal cancer.  The
> first one was surgically removed 2-3 years ago, but a second tumor
> rapidly appeared.  He has gone through radiotherapy and chemiotherapy
> for the past 18 months or so, and he has a tumor which doctors cannot
> remove because it is "too invasive" and the operation would likely
> kill him.  Chemiotherapy has apparently reduced slightly the size of
> the tumor, but it still cannot be removed surgically.  Doctors
> continue to provide him with "short" chemiotherapy sessions (6-8
> weeks) with scans and {*filter*} samples in-between, but they never made
> any statement about a possible outlook.  Sure, it is not a an exact
> science.  Nevertheless I don't expect him to go through chemiotherapy
> for another 10 years.

> I tried to find statistics about the life expectancy of someone with a
> "non-removable" colon tumor (whatever what stage this is, we've never
> been told) but could not find anything on the subject.  If anyone has
> links to point to or similar stories, please let me know.  thanks.

> > My father is 70 and he is fighting is second colorectal cancer.  The
> > first one was surgically removed 2-3 years ago, but a second tumor
> > rapidly appeared.  He has gone through radiotherapy and chemiotherapy
> > for the past 18 months or so, and he has a tumor which doctors cannot
> > remove because it is "too invasive" and the operation would likely
> > kill him.  Chemiotherapy has apparently reduced slightly the size of
> > the tumor, but it still cannot be removed surgically.  Doctors
> > continue to provide him with "short" chemiotherapy sessions (6-8
> > weeks) with scans and {*filter*} samples in-between, but they never made
> > any statement about a possible outlook.  Sure, it is not a an exact
> > science.  Nevertheless I don't expect him to go through chemiotherapy
> > for another 10 years.
> >[...]The most interesting paper
> would probably be this one: Hytrek SD, McLaughlin PJ, Lang CM et al.
> Inhibition of human colon cancer by intermittent opioid receptor
> blockade with naltrexone. Cancer Lett. 1996 Mar 29;101(2):159-64.
> PMID: 8620464. You can find more information at
> http://www.***.com/

> > > My father is 70 and he is fighting is second colorectal cancer. ?The
> > > first one was surgically removed 2-3 years ago, but a second tumor
> > > rapidly appeared. ?He has gone through radiotherapy and chemiotherapy
> > > for the past 18 months or so, and he has a tumor which doctors cannot
> > > remove because it is "too invasive" and the operation would likely
> > > kill him. ?Chemiotherapy has apparently reduced slightly the size of
> > > the tumor, but it still cannot be removed surgically. ?Doctors
> > > continue to provide him with "short" chemiotherapy sessions (6-8
> > > weeks) with scans and {*filter*} samples in-between, but they never made
> > > any statement about a possible outlook. ?Sure, it is not a an exact
> > > science. ?Nevertheless I don't expect him to go through chemiotherapy
> > > for another 10 years.
> > >[...]The most interesting paper
> > would probably be this one: Hytrek SD, McLaughlin PJ, Lang CM et al.
> > Inhibition of human colon cancer by intermittent opioid receptor
> > blockade with naltrexone. Cancer Lett. 1996 Mar 29;101(2):159-64.
> > PMID: 8620464. You can find more information at
> > http://www.***.com/

> Don't believe everything you read. If it's been around and successful with
> cancer, since 1996, there would be clinical trials and there are none for
> naltrexone and cancer.
> 138 for oother diseases and/or conditions but NONE for cancer.
> Save your money. There are multiple spammerss, on various health newsgroups,
> trying to "sell" people on it.
> Suspicions they're sales people. (trying to make money off desperate cancer
> patients).
> J- Hide quoted text -

> - Show quoted text -

> 1: Related Articles, LinksLissoni P, Malugani F, Malysheva O, Kozlov
> V, Laudon M, Conti A, Maestroni G.

> Neuroimmunotherapy of untreatable metastatic solid tumors with
> subcutaneous low-dose interleukin-2, melatonin and naltrexone:
> modulation of interleukin-2-induced antitumor immunity by blocking the
> opioid system.
> Neuro Endocrinol Lett. 2002 Aug;23(4):341-4.
> PMID: 12195238 [PubMed - indexed for MEDLINE]2: Related Articles,
> LinksLissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.

> A new neuroimmunotherapeutic strategy of subcutaneous low-dose
> interleukin-2 plus the long-acting opioid antagonist naltrexone in
> metastatic cancer patients progressing on interleukin-2 alone.
> Neuro Endocrinol Lett. 2002 Jun;23(3):255-8.
> PMID: 12080288 [PubMed - indexed for MEDLINE]3: Related Articles,
> LinksLissoni P, Meregalli S, Fossati V, Barni S, Tancini G, Barigozzi
> P, Frigerio F.

> Radioendocrine therapy of brain tumors with the long acting opioid
> antagonist naltrexone in association with radiotherapy.
> Tumori. 1993 Jun 30;79(3):198-201.
> PMID: 8236504 [PubMed - indexed

> > 1: Related Articles, LinksLissoni P, Malugani F, Malysheva O, Kozlov
> > V, Laudon M, Conti A, Maestroni G.

> > Neuroimmunotherapy of untreatable metastatic solid tumors with
> > subcutaneous low-dose interleukin-2, melatonin and naltrexone:
> > modulation of interleukin-2-induced antitumor immunity by blocking the
> > opioid system.
> > Neuro Endocrinol Lett. 2002 Aug;23(4):341-4.
> > PMID: 12195238 [PubMed - indexed for MEDLINE]2: Related Articles,
> > LinksLissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.

> > A new neuroimmunotherapeutic strategy of subcutaneous low-dose
> > interleukin-2 plus the long-acting opioid antagonist naltrexone in
> > metastatic cancer patients progressing on interleukin-2 alone.
> > Neuro Endocrinol Lett. 2002 Jun;23(3):255-8.
> > PMID: 12080288 [PubMed - indexed for MEDLINE]3: Related Articles,
> > LinksLissoni P, Meregalli S, Fossati V, Barni S, Tancini G, Barigozzi
> > P, Frigerio F.

> > Radioendocrine therapy of brain tumors with the long acting opioid
> > antagonist naltrexone in association with radiotherapy.
> > Tumori. 1993 Jun 30;79(3):198-201.
> > PMID: 8236504 [PubMed - indexed

> And how was life expectancy affected, if at all?
> J- Hide quoted text -

> - Show quoted text -

> A new neuroimmunotherapeutic strategy of subcutaneous low-dose
> interleukin-2 plus the long-acting opioid antagonist naltrexone in
> metastatic cancer patients progressing on interleukin-2 alone.Lissoni
> P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.
> Division of Radiation Oncology, S. Gerardo Hospital, Monza, Milan,
> Italy.

> OBJECTIVES: Recent advances in knowledge of Psychoneuroimmunology have
> shown that several neuroactive substances, including neurohormones and
> neuropeptides, may exert immunomodulatory effects. However, despite
> the great variety of potential neuroimmune interactions, at present we
> may recognize two major neuroendocrine systems exerting a
> physiological neuroimmunomodulatory function, consisting of the pineal
> gland and the brain opioid system, provided by immunostimulatory and
> immunosuppressive effects, respectively. Recent in human studies have
> demonstrated the possibility to amplify the biological activity of
> IL-2, the major anticancer cytokine, by pineal indoles. MATERIALS &
> METHODS: The present study was carried out to draw some preliminary in
> human results on the possible immunomodulatory effects of the
> inhibition of the brain opioid activity by a long-acting opioid
> antagonist, naltrexone (NTX). The study was performed in 10 metastatic
> renal cell cancer patients, who had progressed on a previous
> immunotherapeutic cycle with IL-2 alone. Patients were treated with
> the same doses of IL-2 (6 million lU/day subcutaneously for 6 days/
> week for 4 weeks) plus an {*filter*}administration of NTX at a dose of 100
> mg every 2 days. RESULTS: The clinical response consisted of a partial
> response in 1 and a stable disease in 5 patients, whereas the other 4
> patients progressed. Therefore, the percent of non-progressive disease
> was 6/10 (60%). Moreover, mean lymphocyte increase achieved during
> IL-2 plus NTX was significantly higher (P<0.05) than that obtained
> during the previous treatment with IL-2 alone. CONCLUSIONS: This study
> shows that a blockade of the brain opioid system, which plays a
> physiological immunosuppressive role, may improve the anticancer
> effects of IL-2 in humans.

> PMID: 12080288 [PubMed - indexed for MEDLINE]